Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter
نویسندگان
چکیده
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose give, and 2) for how long? The issue optimal duration has been subject several randomized trials is especially pertinent in context a global BCG shortage. Despite this, there appears uncertainty as whether or may compromised event As such, we wish summarize available evidence an aid practicing urologist.
منابع مشابه
Oral bacillus Calmette-Guérin vaccine against tuberculosis: why not?
The bacillus Calmette-Guérin (BCG) vaccine is the only licensed vaccine for human use against tuberculosis (TB). Although controversy exists about its efficacy, the BCG vaccine is able to protect newborns and children against disseminated forms of TB, but fails to protect adults against active forms of TB. In the last few years, interest in the mucosal delivery route for the vaccine has been in...
متن کاملEpididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.
OBJECTIVE To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin (BCG) and to review the incidence of this adverse effect. DATA SOURCES Information about the patient was obtained from the medical chart. A MEDLINE search of English-language literature (from January 1976 to April 1999) was conducted. STUDY SELECTION All ca...
متن کاملManaging the adverse events of intravesical bacillus Calmette-Guérin therapy.
This paper provides recommendations on the management of complications arising from intravesical treatment with bacillus Calmette-Guérin (BCG) for nonmuscle-invasive bladder tumors. There is minimal recommendations currently available as randomized trials on the side effects of intravesical BCG are lacking and severe complications are usually described in case reports only. All physicians givin...
متن کاملIntravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Intravesical Bacillus Calmette-Guérin (BCG) is considered to be one of the most effective treatments for superficial bladder cancer. Although the mechanisms by which BCG inhibits tumor growth are not known, previous studies have shown that systemic immunization to BCG and the local expression of the immune response in the bladder are associated with a favorable response to BCG therapy. We have ...
متن کاملThirty-five years of intravesical bacillus Calmette-Guérin for bladder cancer: where now?
It is 35 yr since Morales described the use of intravesical bacillus Calmette-Guérin (BCG) for non–muscle invasive bladder cancer (BC). In the interveningyearswehave learned much about this treatment. Although BCG is one of the most studied medicines in urology, many questions regarding its use remain [1]. In this month’s European Urology, Herr et al report their use of induction BCG for high-r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bladder cancer
سال: 2022
ISSN: ['2352-3727', '2352-3735']
DOI: https://doi.org/10.3233/blc-211648